Radiopharm Theranostics Limited (AU:RAD)
ASX:RAD
Want to see AU:RAD full AI Analyst Report?
Top Page
Radiopharm Theranostics Limited
(Sydney:RAD)
Select Model
Select Model
Rating:55Neutral
Price Target:
AU$0.02
▲(5.00% Upside)
Action:UpgradedDate:12/30/25
The score is primarily held back by weak financial quality—large losses and significant negative free cash flow—despite improving revenue and gross margin and a debt-free balance sheet. Technical signals are modestly supportive, while valuation is constrained by negative earnings and the absence of a dividend.
Positive Factors
Revenue acceleration
A ~390% YoY revenue inflection in FY2025 indicates meaningful commercial traction and expanding market adoption. Sustained revenue growth creates a larger base to absorb fixed costs and supports long-term scalability and investment in product development and commercialization.
Negative Factors
High cash burn
Material negative operating and free cash flow (~-36.6M) shows the company is consuming cash faster than it generates it. Persistently high burn creates ongoing reliance on external financing, risking dilution or funding gaps that can constrain long-term strategy execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue acceleration
A ~390% YoY revenue inflection in FY2025 indicates meaningful commercial traction and expanding market adoption. Sustained revenue growth creates a larger base to absorb fixed costs and supports long-term scalability and investment in product development and commercialization.
Read all positive factors
Radiopharm Theranostics Limited (RAD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$70.88M
Dividend YieldN/A
Average Volume (3M)4.84M
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue Growth116.02%
EPS Growth75.56%
CountryAU
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding3,544,216,000
10 Day Avg. Volume4,365,338
30 Day Avg. Volume4,842,346
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.02
Price to Sales (P/S)3.42
P/FCF Ratio-1.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$1.13M
Radiopharm Theranostics Limited Business Overview & Revenue Model
Company Description
Radiopharm Theranostics Limited develops radiopharmaceutical products for diagnostic and therapeutic uses. The company was incorporated in 2021 and is based in Carlton, Australia....
How the Company Makes Money
null...
Radiopharm Theranostics Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
67
Positive
Cash Flow
23
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.35M | 13.40M | 299.23K | 292.36K | 8.83K | 0.00 |
| Gross Profit | 21.33M | 9.81M | -21.31M | -3.00M | -2.97M | 0.00 |
| EBITDA | -43.11M | -31.65M | -45.38M | -37.11M | -18.04M | -484.75K |
| Net Income | -44.94M | -36.70M | -47.95M | -34.61M | -30.34M | -485.19K |
Balance Sheet | ||||||
| Total Assets | 91.17M | 86.48M | 72.04M | 74.95M | 83.38M | 33.44K |
| Cash, Cash Equivalents and Short-Term Investments | 34.52M | 29.12M | 18.58M | 11.70M | 26.98M | 27.09K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 59.00K |
| Total Liabilities | 41.23M | 43.61M | 44.68M | 29.37M | 20.42M | 158.14K |
| Stockholders Equity | 51.78M | 44.79M | 28.12M | 44.38M | 62.96M | -124.70K |
Cash Flow | ||||||
| Free Cash Flow | -37.10M | -36.65M | -22.98M | -24.73M | -38.25M | -32.91K |
| Operating Cash Flow | -37.10M | -36.65M | -22.98M | -23.20M | -9.91M | -32.91K |
| Investing Cash Flow | -6.54M | 1.77M | 0.00 | -1.53M | -28.37M | 0.00 |
| Financing Cash Flow | 42.26M | 45.43M | 29.88M | 9.22M | 65.11M | 60.00K |
Radiopharm Theranostics Limited Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Negative
47.25
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RAD, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.25 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:RAD.
Radiopharm Theranostics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$70.88M | -0.82 | -93.08% | ― | 116.02% | 75.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$7.77M | -0.15 | 2844.96% | ― | ― | 62.07% | |
42 Neutral | AU$28.32M | -6.84 | -49.25% | ― | ― | 25.00% | |
42 Neutral | AU$54.68M | -5.28 | -62.49% | ― | ― | -13.64% | |
41 Neutral | AU$40.47M | -4.45 | -93.66% | ― | -23.71% | -16.02% | |
41 Neutral | AU$138.81M | -2.84 | 279.21% | ― | ― | -37.23% |
* Healthcare Sector Average
AU:RAD
Radiopharm Theranostics Limited
0.02
>-0.01
-13.64%
AU:1AI
Living Cell Technologies
0.01
<0.01
30.00%
AU:PTX
Prescient Therapeutics Limited
0.05
<0.01
6.00%
AU:PIQ
Proteomics International Laboratories Ltd.
0.19
-0.18
-48.61%
AU:CHM
Chimeric Therapeutics Ltd.
0.15
-0.03
-14.71%
AU:RCE
Recce Pharmaceuticals Ltd.
0.51
0.22
77.19%
Radiopharm Theranostics Limited Corporate Events
Radiopharm Theranostics reshapes finance and governance team under Acclime partnership
May 1, 2026
Radiopharm Theranostics has announced a series of senior financial and corporate governance changes, with the resignation of Chief Financial Officer and Joint Company Secretary Phillip Hains. The company will continue to outsource core finance and...
Radiopharm Theranostics advances radiopharmaceutical pipeline with key trial milestones
Apr 22, 2026
Radiopharm Theranostics reported continued momentum in the March 2026 quarter as it advances a diversified pipeline of radiopharmaceutical diagnostics and therapeutics. The company is targeting large oncology markets where current options are limi...
Radiopharm Unveils Encouraging First-in-Human Data for HER2 Radiopharmaceutical 177Lu-RAD202
Apr 19, 2026
Radiopharm Theranostics reported initial first-in-human data from its Phase 0/1 HEAT trial of 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical therapy, in heavily pre-treated patients with advanced HER2-positive solid tumors. Data ...
Radiopharm completes U.S. Phase 2b enrolment for RAD 101 brain metastasis imaging trial
Apr 15, 2026
Radiopharm Theranostics has completed enrolment in its U.S. Phase 2b imaging trial of RAD 101, a novel FASN-targeting radiopharmaceutical being evaluated for diagnosing recurrent brain metastases across a range of solid tumours. Interim data show ...
Radiopharm Director Adjusts Share and Option Holdings
Mar 31, 2026
Radiopharm Theranostics has disclosed a change in the interests of director Ian Turner, detailing adjustments to his direct and indirect holdings in the company’s shares and options. The filing indicates the expiry of a tranche of unlisted o...
Radiopharm’s RAD101 Hits 90% Concordance in Phase 2b Brain Metastases Trial
Mar 23, 2026
Radiopharm Theranostics reported second interim results from its U.S. Phase 2b imaging trial of RAD101 in brain metastases, showing 90% concordance between RAD101 PET imaging and MRI in 18 of 20 evaluable patients, meeting the study’s primar...
Radiopharm Theranostics to spotlight oncology pipeline at NWR Virtual Healthcare Conference
Mar 18, 2026
Radiopharm Theranostics will present at the NWR Virtual Healthcare Conference, with CEO and managing director Riccardo Canevari scheduled to speak on 25 March 2026, and a recording of the session to be made available online afterward. The event of...
Radiopharm Theranostics Narrows Asset Base as Half-Year Loss Widens, Increases Stake in MD Anderson JV
Feb 27, 2026
Radiopharm Theranostics reported a 44% increase in its half-year loss to A$26.97 million for the six months ended 31 December 2025, with net tangible assets per share declining to 0.14 cents from 0.18 cents a year earlier. The company did not decl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.